Royal DSM N.V., the global Life Sciences and Materials Sciences company
headquartered in the Netherlands, North China Pharmaceutical Group Corporation
Ltd. (NCPC GroupCo) of Shijiazhuang, Hebei Province, People’s Republic of
China, NCPC ListCo, the listed affiliate of NCPC and the State-owned Assets
Supervision and Administration Commission of the State Council (SASAC) of
Hebei Province today announce that they have signed the contracts regarding
investment by DSM in NCPC GroupCo and the establishment of three joint
ventures in the areas of nutritional products and anti-infectives.
These contracts are the follow-up to the announcements made at the end of 2004
and the further detailing of the agreement in late 2005. DSM will make a
strategic investment in NCPC by obtaining a minority share (close to 10%) in
NCPC GroupCo. Parties will establish one nutrition production joint venture
(Vitamin C) and two anti-infectives business joint ventures (anti-infectives
active pharmaceutical ingredients and intermediates). In the two
anti-infectives joint ventures DSM will have a 51% interest. In the Nutrition
production joint venture, DSM will hold a minority share of 30%.
The total cash investment by DSM following completion, will amount to
approximately USD 110 million. In addition, DSM will with this investment
leverage its technology and management capabilities. NCPC will bring into the
joint ventures their existing factories, producing Vitamin C and beta lactam
antibiotics, as well as their marketing and sales force for antibiotics, which
is in particular geared toward the fast growing domestic markets in China. The
combination of capabilities and competencies of DSM and NCPC will lead to the
world’s best possible combination of technologies and low cost manufacturing,
while securing high quality and benefiting from the global DSM sales network.
Meanwhile, NCPC and DSM will continue working on preparation and securing
approval for the establishment of these joint ventures. It is expected that
the implementation of the agreements will start somewhere in the second half
of 2009. Furthermore, DSM and NCPC are still discussing possible additional
projects for cooperation.
Jan Zuidam,
DSM’s Deputy Chairman of the Managing Board, comments: “This is a major step
in the context of DSM’s strategy Vision 2010. It serves key strategic targets:
strengthening our DSM Nutritional Products as well as our DSM Anti-Infectives
portfolio and expanding our presence in the emerging Chinese market. The
overall strategic partnership with NCPC provides an accelerated growth path
into the Chinese market and will contribute to our target of USD 1.5 billion
sales in China in 2010.”
NCPC
North China Pharmaceutical Group Corporation (NCPC) is
one of the largest vitamin and antibiotics manufacturers in People’s Republic
of China. NCPC is originally started in 1953 in the Hebei Province and now has
eight production technology platforms including microbian pharmaceutical,
chemical synthesis pharmaceutical, biochemical pharmaceutical, modern biotech
pharmaceutical, natural drug extraction, nutritional healthcare products,
bio-energy and biochemicals. In 2007, NCPC achieved sales revenue of RMB 6.42
billion.
DSM in China
DSM began trading with China in 1963. Today, DSM
has invested in China for over a decade. DSM is currently involved in 9 joint
ventures, 16 wholly-owned foreign enterprises companies in China that employ
nearly 4,000 people. DSM’s business is growing steadily in China with revenue
in 2008 of more than USD 1.1 billion. More information:
www.dsm.com.cn.
